Vagus Nerve Stimulation Shows Positive Treatment Effect in Depression

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Jan. 3, 2025 -- Vagus nerve stimulation (VNS) shows a positive treatment effect and improved quality of life (QoL) among patients with treatment-resistant depression (TRD), according to two studies published online Dec. 18 in Brain Stimulation.

Charles R. Conway, M.D., from Washington University in St. Louis, and colleagues conducted a multicenter, double-blind trial involving 493 adults with treatment-resistant major depression who were randomly assigned to receive 12 months of active or no stimulation sham VNS; 88.4 percent of participants completed the trial. The researchers found that the percent time in Montgomery-Åsberg Depression Rating Scale response could not differentiate active from sham VNS. However, antidepressant benefits significantly favored active VNS based on ratings from on-site clinicians and offsite masked raters. Significantly more percent time in response on the Clinical Global Inventory-Impression and Quick Inventory of Depressive Symptomology-Self Report was seen with active VNS.

A. John Rush, M.D., from Duke-NUS Medical School in Singapore, and colleagues compared the effects of active versus sham VNS on QoL and function in TRD in a multicenter, randomized study involving 493 adult patients with four or more unsuccessful antidepressant treatment trials. The researchers found that active VNS was superior to sham in terms of mean change from baseline in the seven-item subset of the Quality-of-Life Enjoyment and Satisfaction Questionnaire (Mini-Q-LES-Q) and Work Productivity and Activity Impairment Questionnaire (WPAI) item 6 used as continuous variables; a similar trend was seen for Q-LES-Q. Based on the Mini-Q-LES-Q, WPAI item 6, and Q-LES-Q, active VNS was superior to sham in time spent in clinically meaningful benefit.

"What's really important here is that patients themselves were reporting that their lives were improving," Conway said in a statement.

Several authors disclosed ties to pharmaceutical and medical technology companies, including LivaNova; LivaNova funded the original study from which these findings were derived.

Abstract/Full Text - Conway

Abstract/Full Text - Rush

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords